Febrile neutropenia

Home Contact

The MASCC* risk-index score for identification of low- and high-risk patients at presentation with febrile neutropenia

Burden of illness No or mild symptoms
Noderate symptoms
Severe symptoms
No hypotension (systolic BP > 90 mm Hg)
No chronic obstructive pulmonary disease
Solid tumor or hematological malignancy with no previous fungal infection
No dehydration requiring parenteral fluids
Outpatient status
Age <60 yearss
* The Multinational Association of Supportive Care in Cancer
References:
1. Uys A, Rapoport B, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk index score. Support Care Cancer 12:555–560
Important!
Additional recommended reading:
1. ESMO Clinical Practice Guidelines. [Annals of Oncology 21 (Supplement 5): v252–v256, 2010. doi:10.1093/annonc/mdq196] http://www.esmo.org/Guidelines/Supportive-Care/Management-of-Febrile-Neutropenia
2. Support Care Cancer. 2013 Aug;21(8):2303-8. doi: 10.1007/s00520-013-1787-6. Epub 2013 Mar 22. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia. Ahn S1, Lee YS, Lim KS, Lee JL.